Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350545 · ClinicalTrials.gov registry record · NA
A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 37
- Enrollment target
NCT00350545: Completed NA study, sponsored by Stanford University.
NCT00350545 is a NA study that has completed, run by Stanford University. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00350545, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
Study Summary
The addition of rituximab to prednisone for the initial treatment of chronic GVHD will increase the overall response rate, enable a more rapid and effective steroid taper.
Interventions
- DRUG Rituximab
- DRUG Prednisone
- DRUG Cyclosporine A
- DRUG tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2006-08 |
| Est. Completion | 2014-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00350545
The ClinicalTrials.gov registry entry for NCT00350545 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rituximab is the first listed.
NCT00350545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00350545 about?
NCT00350545 is a clinical study titled "A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease". The addition of rituximab to prednisone for the initial treatment of chronic GVHD will increase the overall response rate, enable a more rapid and effective steroid taper.
What is the current status of trial NCT00350545?
This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2006-08. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00350545?
The interventions under investigation include: Rituximab (DRUG), Prednisone (DRUG), Cyclosporine A (DRUG), tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00350545?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.